{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:10:29Z","timestamp":1791807029025,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2024,12,28]]},"DOI":"10.1038\/s41416-024-02883-5","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T10:02:31Z","timestamp":1730368951000},"page":"1901-1912","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Temporal dynamics of immune cell patterns in bladder cancer patients receiving Bacillus Calmette-Gu\u00e9rin therapy"],"prefix":"10.1038","volume":"131","author":[{"given":"Jiang-Li","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Lin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Dan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ling","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao-Nong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neng-Qiao","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding-Kang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Jin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Ya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Yu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Ke","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1944-8281","authenticated-orcid":false,"given":"Chris Zhiyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-0395","authenticated-orcid":false,"given":"Yun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"2883_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81:75\u201394.","journal-title":"Eur Urol"},{"key":"2883_CR2","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","volume":"34","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Sylvester RJ, B\u00f6hle A, Palou J, Lamm DL, Brausi M, et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol. 2016;34:1935\u201344.","journal-title":"J Clin Oncol"},{"key":"2883_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nrurol.2017.16","volume":"14","author":"AM Kamat","year":"2017","unstructured":"Kamat AM, Colombel M, Sundi D, Lamm D, Boehle A, Brausi M, et al. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat Rev Urol. 2017;14:244\u201355.","journal-title":"Nat Rev Urol"},{"key":"2883_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrurol.2014.15","volume":"11","author":"G Redelman-Sidi","year":"2014","unstructured":"Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer-a current perspective. Nat Rev Urol. 2014;11:153\u201362.","journal-title":"Nat Rev Urol"},{"key":"2883_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0022-5347(17)43909-7","volume":"137","author":"TL Ratliff","year":"1987","unstructured":"Ratliff TL, Gillen D, Catalona WJ. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol. 1987;137:155\u20138.","journal-title":"J Urol"},{"key":"2883_CR6","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1158\/2326-6066.CIR-16-0267","volume":"5","author":"M Kates","year":"2017","unstructured":"Kates M, Nirschl T, Sopko NA, Matsui H, Kochel CM, Reis LO, et al. Intravesical BCG induces CD4+ T-cell expansion in an immune competent model of bladder cancer. Cancer Immunol Res. 2017;5:594\u2013603.","journal-title":"Cancer Immunol Res"},{"key":"2883_CR7","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/S0022-5347(17)37668-1","volume":"147","author":"S Prescott","year":"1992","unstructured":"Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol. 1992;147:1636\u201342.","journal-title":"J Urol"},{"key":"2883_CR8","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S0022-5347(17)35678-1","volume":"150","author":"TL Ratliff","year":"1993","unstructured":"Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol. 1993;150:1018\u201323.","journal-title":"J Urol"},{"key":"2883_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1442-2042.1997.tb00143.x","volume":"4","author":"S Honda","year":"1997","unstructured":"Honda S, Sakamoto Y, Fujime M, Kitagawa R. Immunohistochemical study of tumor-infiltrating lymphocytes before and after intravesical bacillus Calmette-Gu\u00e9rin treatment for superficial bladder cancer. Int J Urol. 1997;4:68\u201373.","journal-title":"Int J Urol"},{"key":"2883_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.615091","volume":"11","author":"CJ Lim","year":"2020","unstructured":"Lim CJ, Nguyen PHD, Wasser M, Kumar P, Lee YH, Nasir NJM, et al. Immunological hallmarks for clinical response to BCG in bladder cancer. Front Immunol. 2020;11:615091.","journal-title":"Front Immunol"},{"key":"2883_CR11","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1159\/000474862","volume":"21","author":"C Boccafoschi","year":"1992","unstructured":"Boccafoschi C, Montefiore F, Pavesi M, Pastormerlo M, Annoscia S, Lozzi C, et al. Immunophenotypic characterization of the bladder mucosa infiltrating lymphocytes after intravesical BCG treatment for superficial bladder carcinoma. Eur Urol. 1992;21:304\u20138.","journal-title":"Eur Urol"},{"key":"2883_CR12","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s00345-019-02896-3","volume":"38","author":"C Delcourt","year":"2020","unstructured":"Delcourt C, Gemival P, Nouhaud FX, Gobet F, Gillibert A, Ferlicot S, et al. Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC). World J Urol. 2020;38:1517\u201324.","journal-title":"World J Urol"},{"key":"2883_CR13","doi-asserted-by":"publisher","first-page":"34066","DOI":"10.18632\/oncotarget.26122","volume":"9","author":"A Hashizume","year":"2018","unstructured":"Hashizume A, Umemoto S, Yokose T, Nakamura Y, Yoshihara M, Shoji K, et al. Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin. Oncotarget. 2018;9:34066\u201378.","journal-title":"Oncotarget"},{"key":"2883_CR14","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","volume":"26","author":"M Kates","year":"2020","unstructured":"Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, et al. Adaptive immune resistance to intravesical BCG in non-muscle invasive bladder cancer: implications for prospective BCG-unresponsive trials. Clin Cancer Res. 2020;26:882\u201391.","journal-title":"Clin Cancer Res"},{"key":"2883_CR15","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1007\/s00345-019-03065-2","volume":"38","author":"AM Aydin","year":"2020","unstructured":"Aydin AM, Baydar DE, Hazir B, Babaoglu B, Bilen CY. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy. World J Urol. 2020;38:2537\u201345.","journal-title":"World J Urol"},{"key":"2883_CR16","doi-asserted-by":"publisher","first-page":"5554","DOI":"10.3390\/cancers15235554","volume":"15","author":"M Rodr\u00edguez-Izquierdo","year":"2023","unstructured":"Rodr\u00edguez-Izquierdo M, Del Ca\u00f1izo CG, Rubio C, Reina IA, Hern\u00e1ndez Arroyo M, Rodr\u00edguez Antol\u00edn A, et al. Immune predictors of response after Bacillus Calmette-Gu\u00e9rin treatment in non-muscle-invasive bladder cancer. Cancers. 2023;15:5554.","journal-title":"Cancers"},{"key":"2883_CR17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20240045","volume":"221","author":"MA Tran","year":"2024","unstructured":"Tran MA, Youssef D, Shroff S, Chowhan D, Beaumont KG, Sebra R, et al. Urine scRNAseq reveals new insights into the bladder tumor immune microenvironment. J Exp Med. 2024;221:e20240045.","journal-title":"J Exp Med"},{"key":"2883_CR18","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/1055-9965.EPI-18-0893","volume":"28","author":"A Salmasi","year":"2019","unstructured":"Salmasi A, Elashoff DA, Guo R, Upfill-Brown A, Rosser CJ, Rose JM, et al. Urinary cytokine profile to predict response to intravesical BCG with or without HS-410 therapy in patients with non-muscle-invasive bladder cancer. Cancer Epidemiol Biomark Prev. 2019;28:1036\u201344.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2883_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.668340","volume":"8","author":"CuentasE Parra","year":"2021","unstructured":"Parra Cuentas E. Methods to determine and analyze the cellular spatial distribution extracted from multiplex immunofluorescence data to understand the tumor microenvironment. Front Mol Biosci. 2021;8:668340.","journal-title":"Front Mol Biosci"},{"key":"2883_CR20","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nmeth.1322","volume":"6","author":"JR Wi\u015bniewski","year":"2009","unstructured":"Wi\u015bniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods. 2009;6:359\u201362.","journal-title":"Nat Methods"},{"key":"2883_CR21","doi-asserted-by":"publisher","first-page":"45.e23","DOI":"10.1016\/j.urolonc.2013.06.008","volume":"32","author":"R Nunez-Nateras","year":"2014","unstructured":"Nunez-Nateras R, Castle EP, Protheroe CA, Stanton ML, Ocal TI, Ferrigni EN, et al. Predicting response to bacillus Calmette-Gu\u00e9rin (BCG) in patients with carcinoma in situ of the bladder. Urol Oncol. 2014;32:45.e23\u201345.e30.","journal-title":"Urol Oncol"},{"key":"2883_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00262-016-1945-z","volume":"66","author":"R Pichler","year":"2017","unstructured":"Pichler R, Gruenbacher G, Culig Z, Brunner A, Fuchs D, Fritz J, et al. Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer. Cancer Immunol Immunother. 2017;66:427\u201340.","journal-title":"Cancer Immunol Immunother"},{"key":"2883_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12672-022-00482-5","volume":"13","author":"N Goda","year":"2022","unstructured":"Goda N, Sasada S, Shigematsu H, Masumoto N, Arihiro K, Nishikawa H, et al. The ratio of CD8+lymphocytes to tumor-infiltrating suppressive FOXP3+ effector regulatory T cells is associated with treatment response in invasive breast cancer. Discov Oncol. 2022;13:27.","journal-title":"Discov Oncol"},{"key":"2883_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13000-018-0770-4","volume":"13","author":"Y Liang","year":"2018","unstructured":"Liang Y, L\u00fc W, Zhang X, L\u00fc B. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer. Diagn Pathol. 2018;13:93.","journal-title":"Diagn Pathol"},{"key":"2883_CR25","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","volume":"30","author":"M Miyara","year":"2009","unstructured":"Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30:899\u2013911.","journal-title":"Immunity"},{"key":"2883_CR26","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nm.4086","volume":"22","author":"T Saito","year":"2016","unstructured":"Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, et al. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 2016;22:679\u201384.","journal-title":"Nat Med"},{"key":"2883_CR27","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/S0022-5347(01)65185-1","volume":"157","author":"AR Zlotta","year":"1997","unstructured":"Zlotta AR, Drowart A, Van Vooren JP, de Cock M, Pirson M, Palfliet K, et al. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer. J Urol. 1997;157:492\u20138.","journal-title":"J Urol"},{"key":"2883_CR28","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.eururo.2022.09.008","volume":"82","author":"T Strandgaard","year":"2022","unstructured":"Strandgaard T, Lindskrog SV, Nordentoft I, Christensen E, Birkenkamp-Demtr\u00f6der K, Andreasen TG, et al. Elevated T-cell exhaustion and urinary tumor DNA levels are associated with Bacillus Calmette-Gu\u00e9rin failure in patients with non-muscle-invasive bladder cancer. Eur Urol. 2022;82:646\u201356.","journal-title":"Eur Urol"},{"key":"2883_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2023.07.014","volume":"85","author":"T Strandgaard","year":"2024","unstructured":"Strandgaard T, Nordentoft I, Birkenkamp-Demtr\u00f6der K, Salminen L, Prip F, Rasmussen J, et al. Field cancerization is associated with tumor development, T-cell exhaustion, and clinical outcomes in bladder cancer. Eur Urol. 2024;85:82\u201392.","journal-title":"Eur Urol"},{"key":"2883_CR30","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.eururo.2023.01.017","volume":"83","author":"NM Hahn","year":"2023","unstructured":"Hahn NM, O\u2019Donnell MA, Efstathiou JA, Zahurak M, Rosner GL, Smith J. et al. A Phase 1 Trial of Durvalumab in combination with Bacillus Calmette-Guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. Eur Urol. 2023;83:486\u201394.","journal-title":"Eur Urol"},{"key":"2883_CR31","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1084\/jem.20182031","volume":"216","author":"K Tretina","year":"2019","unstructured":"Tretina K, Park E-S, Maminska A, MacMicking JD. Interferon-induced guanylate-binding proteins: Guardians of host defense in health and disease. J Exp Med. 2019;216:482\u2013500.","journal-title":"J Exp Med"},{"key":"2883_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S1043-4666(02)00490-8","volume":"21","author":"Y Luo","year":"2003","unstructured":"Luo Y, Chen X, O\u2019Donnell MA. Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect. Cytokine. 2003;21:17\u201326.","journal-title":"Cytokine"},{"key":"2883_CR33","doi-asserted-by":"publisher","first-page":"771","DOI":"10.4049\/jimmunol.1300377","volume":"192","author":"F Forster","year":"2014","unstructured":"Forster F, Paster W, Supper V, Schatzlmaier P, Sunzenauer S, Ostler N, et al. Guanylate binding protein 1-mediated interaction of T cell antigen receptor signaling with the cytoskeleton. J Immunol. 2014;192:771\u201381.","journal-title":"J Immunol"},{"key":"2883_CR34","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3389\/fonc.2019.00523","volume":"9","author":"X Chen","year":"2019","unstructured":"Chen X, Jiang F, Jia C, Liu M, Nan Y, Qu L, et al. Comprehensive gene expression analysis in NMIBC Using RNA-seq reveals new therapy strategies. Front Oncol. 2019;9:523.","journal-title":"Front Oncol"},{"key":"2883_CR35","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1084\/jem.20181003","volume":"215","author":"YNS Wong","year":"2018","unstructured":"Wong YNS, Joshi K, Khetrapal P, Ismail M, Reading JL, Sunderland MW, et al. Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. J Exp Med. 2018;215:2748\u201359.","journal-title":"J Exp Med"},{"key":"2883_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22465-w","volume":"12","author":"SV Lindskrog","year":"2021","unstructured":"Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtr\u00f6der K, et al. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun. 2021;12:2301.","journal-title":"Nat Commun"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02883-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02883-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02883-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T17:02:53Z","timestamp":1733763773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02883-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,28]]}},"alternative-id":["2883"],"URL":"https:\/\/doi.org\/10.1038\/s41416-024-02883-5","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]},"assertion":[{"value":"8 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all patients. This study has been approved by the ethics committee of the Sun Yat-sen University Cancer Centre (B2022-201-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}